Cancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer.
The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is designed to stimulate the body’s immune system to attack cancer cells. It will deliver cancer-associated antigens (MAGE A3 and NY-ESO-1) to antigen presenting cells called dendritic cells, causing the immune system to produce cytotoxic T cells, which target and kill cancerous cells expressing the antigens.
{iframe}https://medicalxpress-com.cdn.ampproject.org/c/s/medicalxpress.com/news/2019-12-first-in-human-trial-lung-cancer-immunotherapy.amp{/iframe}